Evolving chemotherapeutics

Bridging Trial Recruiting at Dose Level 4

The bridging PK study of Deflexifol is progressing well. Study chief investigator Associate Professor Daniel Brungs reports that patients are being recruited to Dose Level 4. 14 patients have been treated so far. The study appears to reinforce earlier findings about the safety and tolerability of Deflexifol – with patients tolerating 40% higher dosing than Standard of Care to date. The study is expected to finish recruiting patients in the next two months.